(SAA-LDL) is formed by an oxidative interaction and is considered to be a new marker related to oxidative modification of LDL. As the effect of smoking on oxidized LDL is of concern, this study investigated the association between SAA-LDL and smoking status. A total of 578 Japanese obese outpatients (mean ± SD age 50.5 ± 14.3 years) were studied. Smoking status was examined via a selfreported questionnaire. Cardio metabolic variables, including high-sensitivity Creactive protein (hsCRP), were analysed in addition to SAA-LDL. There was an increasing trend in SAA-LDL levels from non-to ex-to current smokers, and significantly higher SAA-LDL levels were observed in current smokers versus nonsmokers (median SAA-LDL level 36 µg/ml versus 28 µg/ml, respectively). This significant difference was reduced after adjusting for multiple confounders, including lipid levels. Smoking may be associated with increased levels of SAA-LDL in an obese Japanese population, but further studies are needed.
Introduction
While cigarette smoking is recognized as an atherosclerotic risk factor, the underlying mechanisms associated with the involvement of smoking in atherosclerosis remain to be elucidated. 1, 2 Reactive oxygen species, oxidized low-density lipoprotein (LDL) and inflammation, which are all induced by smoking, have been investigated to determine the effects of smoking on atherosclerosis. 1, 2 Chronic low-grade inflammation, as indicated by high-K Kotani, N Satoh-Asahara, Y Kato et al.
SAA-LDL levels and smoking sensitivity C-reactive protein (hsCRP) levels, is thought to be a secondary effect of smoking and a marker of tissue injury; thus, inflammation can persist (i.e. in the form of continuous high levels of hsCRP) long after the cessation of smoking. 3, 4 Metabolic alterations after smoking cessation (e.g. weight gain) can also partly contribute to the persistent inflammatory state. 4 Several studies have reported a positive association between oxidative modification of LDL in the circulation and smoking status; 5 -10 however, studies do not always produce consistent results on this subject. 11 This topic should be regularly re-examined as new analytical measures related to oxidized LDL become available. A complex of serum amyloid A (SAA) with LDL is formed by an oxidative interaction between SAA and LDL, and SAA-LDL is considered to be a new marker of oxidatively modified LDL particles. 12 The SAA-LDL level also shows a significantly positive association with the hsCRP level. 12, 13 There is, however, no information on the association between SAA-LDL and smoking status. Thus, the present study investigated the correlation between SAA-LDL and smoking status, compared with hsCRP, in obese Japanese patients.
Patients and methods

STUDY POPULATION
This cross-sectional study investigated hospital-based, obese Japanese outpatients registered in the multicentre Japan Obesity and Metabolic Syndrome Study (JOMS) 13 between April 2007 and March 2011. The present study included obese patients only; those who had a history of overt cardiovascular, kidney, liver or collagen diseases, those with acute infectious diseases such as a common cold, or those currently taking anti-inflammatory medication were excluded. The institutional ethics committee of six clinical centres across Japan approved the study, and all patients provided written informed consent to participate in the study.
DATA COLLECTION
Smoking status (non-smoker, ex-smoker or current smoker) was examined via a structured, self-reported questionnaire. Exsmokers were defined as those who had stopped habitual smoking for > 1 year, and a proportion of them were randomly asked about the length of time since stopping smoking. Each patient's body mass index (BMI; weight [kg] / height [m 2 ]) was calculated. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were determined in the seated patient's right-arm with a standardized sphygmomanometer. Venous blood was obtained from the antecubital vein after an overnight fast of approximately 10 h. The samples were anticoagulated with 2% ethylenediaminetetra-acetic acid and analysed immediately. Serum triglyceride (TG) and fasting plasma glucose (FPG) levels were measured enzymatically, and serum LDLcholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were measured using homogeneous methods, as described previously. 14 Serum SAA-LDL levels were determined using an enzymelinked immunosorbent assay, as described previously. 12 Serum hsCRP levels were determined using an enzyme-linked immunosorbent assay (Assaypro Co. Ltd, St Charles, MO, USA) according to the manufacturer's instructions.
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The within-group trends for each variable K Kotani, N Satoh-Asahara, Y Kato et al.
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were examined using the χ 2 -test, with a residual analysis or a one-way analysis of variance with post-hoc multicomparison tests. A general linear model analysis for SAA-LDL or hsCRP (as a dependent variable) was used to examine the correlation with smoking status (as a fixed variable) after adjusting for confounding variables (as covariables). These analyses were performed with three models: model 1 was adjusted for basic confounders such as age, gender and BMI; model 2 was adjusted for the basic confounders plus SBP and FPG; and model 3 was adjusted for the confounders included in model 2 plus LDL-C, HDL-C and TG. Models 2 and 3 did not include DBP as a variable because of its close correlation with SBP (Pearson's correlation coefficient > 0.7). Pearson's correlation coefficient test was also used to examine the correlation between the length of time since stopping smoking and either SAA-LDL or hsCRP level in the ex-smoker group. TG, hsCRP, SAA-LDL and the length of time since stopping smoking were log-transformed for the analyses because of their skewed distributions. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 578 hospital-based obese Japanese outpatients participated in this study: 262 males and 316 females. Their mean age ± SD was 50.5 ± 14.3 years. The clinical characteristics of the patients according to their smoking status are shown in Table 1 .
There were significantly higher percentages of males (P < 0.01) and significantly higher levels of TG (P < 0.01) in the ex-smoker and current smoker groups compared with the non-smoker group. Significantly lower age (P < 0.01) and HDL-C levels (P < 0.01) were observed in the current smoker group compared with the non-smoker group, and significantly higher levels of FPG were Data presented as mean ± SD, median (interquartile range) or n of patients. a P < 0.01 versus non-smokers; b P < 0.05 versus ex-smokers; c P = 0.01 versus non-smokers. observed in the current smoker group than in the ex-smoker group (P < 0.05). There was an increasing trend in the levels of hsCRP and SAA-LDL from the non-smoker group to the ex-smoker group and to the current smoker group; levels of hsCRP and SAA-LDL were significantly higher (F = 4.51, P = 0.01 and F = 5.61, P < 0.01, respectively) in the current smoker group than in the nonsmoker group.
The results of the general linear model analyses for SAA-LDL revealed that the increase in SAA-LDL levels from the nonsmoker to the ex-smoker and current smoker groups remained independently significant in model 1 (F = 4.53; P = 0.01), and in model 2 (F = 4.40; P = 0.01); however, the correlation with smoking status was no longer significant in model 3. The results of the general linear model analyses for hsCRP revealed that the increase in hsCRP levels observed from the non-smoker to the exsmoker and current smoker groups showed F = 2.86, P = 0.05 in model 1 and the increase was clearly not statistically significant in models 2 or 3.
The selected group of ex-smokers (n = 42; median length of time since stopping smoking 7.5 years [interquartile range 3.0 -18.3 years]) showed a non-significant inverse correlation between the length of time since stopping smoking and SAA-LDL (Pearson's correlation coefficient = -0.276). A similar, but weaker, non-significant correlation was observed between the length of time since stopping smoking and hsCRP (Pearson's correlation coefficient = -0.156).
Discussion
The present study showed a significantly higher level of SAA-LDL in current smokers than in non-smokers and an intermediate level in ex-smokers, in the obese Japanese population that was studied. The trend towards increasing SAA-LDL concentrations from non-smokers to ex-smokers and current smokers was modulated by taking lipid levels into account. Similar trends were observed with hsCRP, although SAA-LDL showed a clearer degree of statistical significance relative to hsCRP. In general, oxidative modification of LDL is one of the keys to a better understanding of the involvement of smoking in atherosclerosis, and smoking is a modifiable habit when trying to control atherosclerotic diseases. Consistent with previous studies, 5 -10 the present study, using the new oxidized LDLrelated marker SAA-LDL, 12 increases understanding of smoking-lipoprotein associations.
There are some biological explanations for the increased oxidative modification of LDL in smokers versus non-smokers. In addition to the fact that smoke contains large levels of oxidants and radicals, the reduced vitamin E content of LDL and increased iron in the circulation of smokers compared with non-smokers may enhance the susceptibility of LDL to oxidative modification. 6, 9 Oxidative damage of tissues, including vessels, occurs with inflammation (as reflected in hsCRP), 3 and there is a continued influence on oxidative modification of LDL. 9, 15 It is interesting to note that the association between SAA-LDL and smoking status observed in the present study was affected by the association of lipid levels with smoking status. Smoking and smoking cessation alter lipid/lipoprotein metabolism. 16 Similar to the present study, the increasing levels of TG and the decreasing levels of HDL-C associated with smoking status have been described previously, 17 There were limitations to the present study. Its cross-sectional design did not clearly elucidate the cause-and-effect relationship and, as the study was conducted in a hospital-based setting, the ability to extrapolate the results to a more general population is limited. The relatively small sample size was a further limitation, particularly for the ex-smoker group. Detailed information on smoking habits (e.g. intensity, age at which smoking started, quantity consumed) and an objective assessment of smoking status (e.g. urinary cotinine measurement) were also lacking.
These issues will be addressed in future work.
In summary, the present study suggested that smoking may be associated with increased levels of SAA-LDL in an obese Japanese population. The general trend indicating an association between SAA-LDL and smoking status appeared to be similar to that for hsCRP. Further studies are needed to clarify the clinical relevance and the mechanisms associated with these findings.
Conflicts of interest
The authors had no conflicts of interest to declare in relation to this article.
